Share this:
Curiosity, unconventional thinking, and random chance drive research into new drugs for the treatment of kidney disease.
Granulomatosis with polyangiitis—yes, it’s a mouthful. It’s also a rare disease, afflicting as few as two in 100,000 people. It’s so uncommon a general practitioner might not recognize it. Says Fernando C. Fervenza, M.D., Ph.D., a Mayo Clinic nephrologist. “A lot of physicians down in the community are probably going to see one case in their lifetime.”
But granulomatosis can be deadly. The body’s immune system attacks itself, causing inflammation of small blood vessels, a condition known as vasculitis. And vasculitis can damage sinuses, lungs, kidneys, eyes, ears, skin, nerves, and joints. Until the 1960s “basically it was fatal,” says Dr. Fervenza, who is often called in on such cases when vasculitis inflames the millions of vessels that populate the kidneys. Read the rest of the article on Discovery's Edge.
__________________________
Find more research news on Discovery's Edge.
Share this:
Related articles
Cardiovascular disease is still the No. 1 killer in the world. The good news is that, generally, the numbers are getting better, with one surprising ...
DEAR MAYO CLINIC: I suffered an injury while working out and my primary care physician ordered an X-ray. However, after reviewing the results, my doctor recommended ...
Experts reframe understanding of treatment impact over time, need for combination therapies ROCHESTER, Minn. — An expert work group has reframed what is clinically meaningful to ...